Author/Authors :
okay, mufide hacettepe university - medical school - department of hematology, Ankara, TURKEY , malkan, umit yavuz university of health sciences - dışkapı yıldırım beyazıt training and research hospital - department of hematology, Ankara, TURKEY , bolek, ertugrul cagri hacettepe university - medical school - department of internal medicine, Ankara, TURKEY , sayinalp, nilgun hacettepe university - medical school - department of hematology, Ankara, TURKEY , buyukasik, yahya hacettepe university - medical school - department of hematology, Ankara, TURKEY , haznedaroglu, ibrahim hacettepe university - medical school - department of hematology, Ankara, TURKEY
Abstract :
Objective: Thrombohemorrhagic events developing in the Philadelphia negative myeloproliferative neoplasms may worsen the clinical course of the disease and increase the morbidity and mortality. The aim of this study is to assess critical risk factors of the hemostatic complications in myeloproliferative neoplasms. Materials and Methods: The patients who were diagnosed as myeloproliferative neoplasm based on world health organization 2016 criteria are included into the study. The categorical and continuous data were compared with Chi-square and independent sample t-test. The statistical significance threshold was considered as p 0.05. Results: 181 patients were evaluated in this study. The number of the patients with polycythemia vera, essential thrombocytosis and primary myelofibrosis were 89, 50 and 42 respectively. At the time of diagnosis, the median age was 54 years. There were 50 patients who had thrombosis at the time of diagnosis, and 22 patients have developed thrombosis during the follow-up. Venous thrombosis is more frequent than arterial thrombosis. The smoking habit was statistically higher in the patient with myeloproliferative neoplasm who developed thrombosis (p=0.006). The most frequent hemorrhagic complication was gastrointestinal bleeding. Platelet levels of patients with complications during the course of myeloproliferative neoplasm were found to be lower than those without complications (p 0.001). Conclusion: The hemostatic complication rates due to myeloproliferative neoplasm were 39% thrombosis and 13% bleeding. While the cigarette usage was significantly higher in the thrombosis group, advanced age, male sex, types of myeloproliferative neoplasm, JAK-2 positivity were similar between the groups. Further experimental and clinical studies should focus on the pathobiology and proper clinical management of the myeloproliferative neoplasm patients with hemostatic complications.